IL28B gene major and relapse of previous treatment/first treatment patient with intrahepatic IFN stimulating gene index&lt

3 trials

Sponsors

Kanazawa University

Conditions

chronic hepatitis C

Unknown Phase

Peg-IFN-alfa2b/Ribavirin/Telaprevir therapy for chronic hepatitis C: Effectiveness prediction by gene analysis and Duration of therapy

RecruitingJPRN-UMIN000008198

Kanazawa Universitychronic hepatitis C

Start: 2012-03-01Target: 200Updated: 2026-06-29

Peg-IFN-alfa/Ribavirin/Simeprevir therapy for chronic hepatitis C: Effectiveness prediction by gene analysis and Duration of therapy

RecruitingJPRN-UMIN000012731

Kanazawa Universitychronic hepatitis C

Start: 2014-01-01Target: 200Updated: 2026-06-29

Peg-IFN-alfa 2b/Ribavirin/Vaniprevir therapy for chronic hepatitis C: Effectiveness prediction by gene analysis and duration of therapy

RecruitingJPRN-UMIN000016639

Kanazawa Universitychronic hepatitis C

Start: 2015-02-01Target: 100Updated: 2026-06-29